Search This Blog

Tuesday, September 3, 2019

Vertex to acquire Semma Therapeutics for $950M

Vertex Pharmaceuticals (NASDAQ:VRTX) has agreed to acquire privately held Semma Therapeutics, a developer of stem cell-derived human islets for the potential cure of type 1 diabetes, for $950M in cash.
The transaction should close next quarter.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)